^
Association details:
| Biomarker: | TP53 S12F + KRAS G12D + TMB-L |
|---|---|
| Cancer: | Small Intestinal Carcinoma |
| Drug: | Tevimbra (tislelizumab-jsgr) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Case report: A case of duodenal adenocarcinoma achieving significantly long survival treating with immune checkpoint inhibitors and chemotherapy without positive biomarkers
Published date:
12/02/2022
Excerpt:
Results of ctDNA suggested the presence of TP53 p.S12F KRAS p.G12D mutations, TMB 2.51 Mut/MB (low)...the patient has received 19 cycles of combination therapy of tislelizumab and irinotecan and three cycles of tislelizumab maintenance therapy...the patient responded well to immunotherapy combined with chemotherapy for 17 months, and the response is still ongoing.
Secondary therapy:
irinotecan
DOI:
https://doi.org/10.3389/fimmu.2022.1046513
